Literature DB >> 3262908

Antibodies to amyloid A protein in rheumatic diseases.

C P Maury1, A M Teppo.   

Abstract

Circulating autoantibodies against amyloid A protein (AA) were demonstrated by enzyme immunoassay in 18/62 patients with rheumatoid arthritis (RA) and in 9/27 patients with systemic lupus erythematosus (SLE). In the subset of RA patients who had developed amyloid, the frequency of antibodies to AA was lower than in those without amyloid (P less than 0.05). The antibody levels showed some variation in serial serum samples during follow-up (1-4 years) of patients with amyloidosis or SLE, but did not correlate with disease activity. In contrast to the patients with rheumatic diseases, patients with inflammatory bowel disease and acute bacterial peritonitis had antibody levels within the range of the healthy control subjects. The results show that autoantibodies to protein AA may occur in rheumatic diseases; their occurrence does not, however, identify subjects with tissue amyloid deposits. Absorption experiments suggest that the antibodies may be directed to circulating amyloid A protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262908     DOI: 10.1007/bf00272431

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  ESTIMATION OF SERUM LIPOPROTEINS USING SULPHATED POLYSACCHARIDES.

Authors:  W G DANGERFIELD; G FAULKNER
Journal:  Clin Chim Acta       Date:  1964-08       Impact factor: 3.786

Review 2.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

3.  Amyloid fibril protein subunit, "protein AS": distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinamia.

Authors:  G Husby; K Sletten; T E Michaelsen; J B Natvig
Journal:  Scand J Immunol       Date:  1973       Impact factor: 3.487

4.  Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis.

Authors:  C P Maury; A M Teppo
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

5.  Amyloid protein SAA is associated with high density lipoprotein from human serum.

Authors:  E P Benditt; N Eriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

6.  Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  C P Maury; A M Teppo; O Wegelius
Journal:  Ann Rheum Dis       Date:  1982-06       Impact factor: 19.103

7.  Characterization of amyloid related protein SAA complexed with serum lipoproteins (apoSAA).

Authors:  G Marhaug; K Sletten; G Husby
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

8.  Human high-density lipoprotein associated amyloid A protein. Structural characteristics, relation to apo A-I and A-II concentrations, and plasma clearance kinetics in the rat.

Authors:  C Ehnholm; A M Teppo; J J Ohisalo; C P Maury
Journal:  Scand J Rheumatol       Date:  1985       Impact factor: 3.641

9.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

10.  Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo.

Authors:  A Husebekk; B Skogen; G Husby; G Marhaug
Journal:  Scand J Immunol       Date:  1985-03       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.